

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dominique P. Bridon et al.
Serial No: 10/565,900
Confirmation No: 6100
Filed: January 24, 2006
For: LONG LASTING INSULIN DERIVATIVES AND
RELATED METHODS THEREOF
Examiner: Christina Bradley
Art Unit: 1654

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being electronically filed in accordance with §1.6(a)(4) on the 1st day of July, 2010.

/Sandra Szela Congdon/
Sandra Szela Congdon, Reg. No. 60,655

Commissioner for Patents

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FILED PURSUANT TO
THE DUTY OF DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this supplemental Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicants hereby make of record in the above-identified application the information listed on the concurrently filed form PTO/SB/08a.

The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicants hereby make the following additional information of record in the above-identified application.

The Applicants would like to bring to the Examiner's attention the enclosed Official Action dated June 3, 2010 for related Canadian Patent Application No. 2,505,617. The reference listed in the Official Action is corresponding Canadian Patent Application, 2,526,957, which has not been previously cited in an Information Disclosure Statement, and is cited herein.

PART III Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Respectfully submitted,

Dominique P. Bridon *et al.*, Applicants

By: /Sandra Szela Congdon/
Sandra Szela Congdon, Reg. No. 60,655
Diana M. Collazo, Reg. No. 46,635
Attorney for Applicants
LANDO & ANASTASI, LLP
Riverfront Office Park
One Main Street
Cambridge, Massachusetts 02142
Tel. (617) 395-7000

Dated: July 1, 2010